Speakers

Speakers Line-up

CHINA

Wu Tai Xiang
Director
Chinese Clinical Trials Registry, China

James Fan
Vice President of Medical and Regulatory Affairs
Protech Pharmaservices Corporation (A+ China), China

Jun WANG
Head of Development Operations
Takeda Development Center Shanghai

Na Guo
Principal Epidemiologist
GSK Shanghai R&D, China

John L. Xu
Chief Scientific Officer
Mab-Venture Biopharm Co., Ltd, China

Dr C.S. Chen M.D., Ph.D.
Executive Director - Cancer Center, Acting Chief of Medicine
Shanghai Jiahui International Hospital, China

James Creeden
Medical Director, Roche Molecular Information – APAC
Roche, China

Jason Yang, MD, PhD.
Chief Medical Officer
CStone Pharmaceuticals, China

George Liu
Vice President, Early Development
Harbour Biomed, China

Eddy Wu
Executive Director, Medical and Scientific Affairs
Allergan, China

George Guo
GMO Country Head
Novartis Pharmaceuticals (China) Oncology, China

Joe Zhou
CEO
Walvax, China

Yao-Chang Xu
CEO
Abbisko Therapeutics Co., Ltd., China

Chenguang Li
Clinical Study Manager, Evidence Generation & Clinical Research
RB, China

Tong Guo
Head of Biostatistics, Africa/Asia
QuintilesIMS, China

 

INTERNATIONAL

Barbara E. Bierer
Faculty Co-Director, Multi-Regional Clinical Trials Center of Harvard and the Brigham and Women’s Hospital (MRCT Center), and Professor of Medicine, Harvard Medical School, United States

Jaclyn Yuen Yeng Ong
Senior Clinical Research Coordinator
Institute of Mental Health, Singapore

 

Speakers Profile

Eddy Wu
Executive Director, Medical and Scientific Affairs
Allergan, China

Eddy WU, Ph.D., is the Executive Medical Director for Allergan China. He  joins Allergan from 2015 and bases in Shanghai.  He has over a decade of local and global industry experience. Before joining Allergan, he worked with Novartis and based in Hong Kong, Taiwan, and Switzerland Basel. He had a track record of success in roles of increasing responsibility for Asia Pacific, Middle East & African Countries (AMAC), he drove several major Clinical development programs and regional studies, in particular PMS, retrospective and head-to-head interventional studies. He also designed and developed speaker training, advisory board programs, treatment guidelines, KOL advocacy and development plans etc.  He has extensive experience on clinical development & medical affairs and was also previously head of Health Economics & Outcome Research (HEOR) for AMAC, China & Japan in Novartis.


James Fan
Vice President of Medical and Regulatory Affairs
Protech Pharmaservices Corporation (A+ China), China

Dr. James Fan, Vice President, Clinical Research and Regulatory Affairs Dept. Generon (Shanghai) Corporation Ltd.  As Senior Medical Director,  James Fan joined ICON in 2006 till July2016, having previously held the position of Medical Director in Taiwan-based CRO, Protech Pharmaservices Corporation, and American Biotech, Optimer Pharmaceuticals, Inc for 7 years.   As a medical monitor and safety physician, he has been medical monitor for more than 50 global clinical trials, his experience also includes pharmacovigilance in the drug development in FDA/EMA, Japan and Asia pacific area. He is co-author for three clinical trial books published by Elsevier contributing to the chapters of pharmacovigilance system setup, and clinical trial in China, Taiwan, and Singapore respectively. 

As a physician of Internal Medicine, he was trained in the Shanghai Medical University Hospital with 11 years of clinical practice experience, and then he was also awarded Master of Business Study by Massey University, New Zealand.


George Guo
GMO Country Head
Novartis Pharmaceuticals (China) Oncology, China

George worked in clinical research area nearly 20 years and has riched experience for global trials. He worked in big pharmaceutical company in the past years  like MSD, Pfizer, Novo Nordisk and GSK etc. Involved in Phase I to IV studies for anti-biotic, immnounlogy, respiratory, cardivasclar, urology, endocrinolgy, and oncology area. Familiar with the FDA, EMA, PMDA and CFDA’s inspection and requirement of clinical trials. Closely worked with DIA and RDPAC for industry initiative and collaborations。

Before joined in the industry, George worked in one of the Beijing Municipal Hospital as a doctor.

He majored in clinical medicine in medical university, and has MBA background.


Chenguang Li
Clinical Study Manager, Evidence Generation & Clinical Research
RB, China

Chenguang Li is regional clinical study manager of Reckitt Benckiser(RB) Healthcare UK, the world's leading consumer health and hygiene company, with brands (such as Nurofen, Strepsils, Mucinex, Dettol, Lysol, Finish and Vanish) sold in nearly 200 countries and operations in over 60 countries.

Chenguang Li brings over 8 years of clinical operation experiences in pharmaceuticals/CRO in china. He has 4 years’ experience in project management, including the Global & Local stuidies, also the CRO management. Chenguang Li is Team-work oriented.  He is very good at communication skills and managing customers’ relationship. 

Chenguang Li has graduated from University of applied science Berlin in 2006. After graduation, he worked for Quintiles, Parexel, Shire, CASI pharmaceutical before joining RB China


James Creeden
Medical Director, Roche Molecular Information – APAC
Roche, China

Dr. James Creeden is Medical Director for Roche Molecular Information in the Asia-Pacific Region, responsible for Foundation Medicine in Asia.  Formerly Medical Director for Roche China, he was responsible for medical strategy and post-registration studies for the Roche and Genentech portfolio in China.  Dr. Creeden holds a PhD in molecular toxicology from Rutgers University and an MD from Robert Wood Johnson Medical School. Before coming to Shanghai, Dr. Creeden was Chief Medical officer for Roche Professional Diagnostics, the world's leading In Vitro Diagnostics manufacturer, from 2008 to 2014.


Na Guo
Principal Epidemiologist
GSK Shanghai R&D, China

Na Guo is a Principal Epidemiologist at GSK Shanghai R&D. She received a B.S. degree in Medicine from Shandong University, Master of Public Health in Clinical Epidemiology from University of Alberta, and Ph.D. in Outcomes Research from University of British Columbia. After 2 years of Post-doctoral research in Health Economics at McMaster University, Na joined Roche Asia-Pacific Product Development in Shanghai in 2012 as an Epidemiologist and later a Real World Data Scientist.


Yao-Chang Xu
CEO
Abbisko Therapeutics Co., Ltd., China

Yao-Chang Xu is currently the founder and CEO of Abbisko Therapeutics Inc, an innovative biopharmaceutical company dedicated to discover and develop innovative medicines.

Before that, Dr. Xu was the general manager of Biomedical Research & Development Center for Hansoh Pharmaceutical Group from 2012 to March of 2016. Prior to that, Dr. Xu was at Novartis Institutes for BioMedical Research Inc. (NIBR) as executive director of Global Discovery Chemistry based in Cambridge, Massachusetts. In 2007, Dr. Xu moved to Shanghai, China, taking an assignment as head of chemistry for China Novartis Institute for Biomedical Research (CNIBR), and responsible for medicinal chemistry, the research phase of DMPK, and analytical and bio-analytical science in China. At the same time, Dr. Xu was a key player in building up the 1.2 billion US dollar Novartis Shanghai Research Center

After obtained BS degree in Nanjing University in 1982, Dr. Xu was the first group of students in chemistry selected by government for oversea higher education. Yao earned his Ph.D. in organic chemistry at the University of Chicago in 1988, and subsequently spent two years as postdoctoral fellow at University of Sherbrooke in Canada.  After worked in cancer research as a senior scientist at BioChem Pharma Inc. for about 3 years, Dr. Xu joined Lilly in 1993 as a Senior Research scientist. At Lilly, he made important contributions to many drug research programs including clinical drug candidates for smoking cessation, depression, migraine, obesity and etc. Dr. Xu was promoted to Principal Scientist in 1997, Research Advisor in 2000, and then Head of Discovery Chemistry Research for Lead Validation in 2001, and then Head for Lead Optimization in 2003..

Dr. Xu was also intimately involved in Lilly external research activities, and was a key member of Lilly management team in building the chemistry research center in China. He spent time in China in 2003 and created the first China outsourcing organization, namely as Lilly / ChemExplorer. This setup has provided an unique staffing strategy for Lilly’s drug discovery research. He acted as CSO for the collaboration during 2004-2005 in Shanghai.


Barbara E. Bierer
Faculty Co-Director, Multi-Regional Clinical Trials Center of Harvard and the Brigham and Women’s Hospital (MRCT Center)and Professor of Medicine, Harvard Medical School, United States

Barbara E. Bierer, MD is Professor of Medicine, Harvard Medical School and Brigham and Women’s Hospital (BWH), Boston and a hematologist/oncologist. She is the faculty co-director of the Multi-Regional Clinical Trials Center of BWH and Harvard (MRCT Center), a University-wide and collaborative effort to improve standards for the planning and conduct of international clinical trials, with a particular focus in the emerging economies. In addition, she is the Director of the Regulatory Foundations, Ethics, and the Law program at the Harvard Catalyst, the Harvard Clinical and Translational Science Award, working across the academic spectrum to enable the clinical trial enterprise from study planning through recruitment to data acquisition and dissemination.  Previously she served as senior vice president, research at the Brigham and Women’s Hospital for over a decade, and as chair of the Secretary’s Advisory Committee on Human Research Protections, HHS.


John L. Xu
Chief Scientific Officer
Mab-Venture Biopharm Co., Ltd, China

Dr. John Xu is currently the CSO at Mab-Venture Biopharm Co., Ltd., in charge of biologics drug R&D in the oncology, autoimmunity, and cardiovascular and metabolic disease areas, from target selection through to Proof-of-Concept clinical studies. Before joining Mab-Venture, Dr. Xu worked at Novartis as Sr. Investigator, Translational Medicine, at GSK as Associate Director, Biologics Drug Discovery, and at Shanghai Benemae Pharmaceutical Corporation as Head of R&D.

Dr. Xu has more than 26 years of international biomedical R&D experience in both academic and industry settings. At Novartis, he contributed to the development of Clinical Development Plan for a number of INDs and applied biomarker strategy to assess the PD and efficacy of these drug candidates in global trials. At Benemae, he led company-wide efforts to conduct IND-enabling studies for a GLP-1 receptor agonist, designed the protocol for a phase I, randomized, double-blind, placebo-controlled, sequential parallel group, MAD study to evaluate the safety, tolerability, pharmacokinetics and early efficacy of the drug in healthy overweight/obese subjects for chronic weight management, and received “safe-to-proceed” feedback from US FDA in July 2016. In addition, a novel mAb drug candidate for the prevention and treatment of thromboembolic disorders will be ready for dual IND/CTA filing with US FDA and CFDA in the first half of 2018.

Dr. Xu received his B.S. degree in Cell Biology from Peking University and Ph.D. degree in Biochemistry from Harvard University. He was the recipient of Damon Runyon Cancer Research Foundation Fellowship when he was a post-doctoral fellow in Immunology at Stanford Medical Center and of NIH R01 Grant when he was an Assistant Professor at the University of Illinois at Urbana-Champaign. 


Jun WANG
Head of Development Operations
Takeda Development Center Shanghai

Mr. Jun WANG serves as the associate director of clinical operations in Takeda Development Center Shanghai, manage regional clinical operations study management team located in both Beijing and Shanghai, guide and lead team work as a completely integrated members of Asia Pacific region and global development team to further contribute compound development activities for China.

Jun was trained in China and has worked in the industry for more than 15 years with extensive project management experience for both pharmaceuticals and CROs, which including 7 years project management regional experience overseas enhancement in the industry across many therapeutic areas.

Jun has the deep knowledge in compound development strategies, clinical operations management, regional regulations across most of Asia Pac countries, CRO outsourcing model management, partnership oversight and vendors category management.


George Liu
Vice President, Early Development
Harbour Biomed, China

Dr. George Liu currently is head of early development at Harbour Biomed. Before joining Harbour Biomed, he was the director of clinical pharmacology for Novartis Oncology where he was responsible for clinical pharmacology of full development of oncology products in China, and was director of dedicated project expert, drug disposition for Sanofi Asia pacific therapeutical strategical unit (AP TSU) while he was in charge of clinical PK for Sanofi in Asia Pacific.

Dr. Liu obtained his BS from Nanjing University in 1990 and Ph. D. from pharmacy school of Purdue University in 1999.  He started his professional career at Xenobiotic Laboratories and has worked for paradigm genetics, Guildford Pharmaceuticals, and GSK with increasing responsibilities on both drug discovery and development, including significant contribution to clinical development and/or regulatory approval of Lusedra®, Anoro®, Ellipta®, Insuman, Mozobil, Signifor ®, LEE011, LDK378, and LCI699.